Spots Global Cancer Trial Database for Five Fraction SABR Dose Escalation for Early Stage Squamous Cell Carcinoma of the Lung

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Five Fraction SABR Dose Escalation for Early Stage Squamous Cell Carcinoma of the Lung

Official Title: Phase I/II Trial Evaluating Five Fraction SABR Dose Escalation for Early Stage Squamous Cell Carcinoma of the Lung

Study ID: NCT03321747

Conditions

Lung Cancer

Interventions

Stereotactic Ablative Body Radiation (SABR)

Study Description

Brief Summary: The purpose of this study is to test whether 5 fraction stereotactic ablative body radiation (SABR) is safe and improves local control for early state squamous cell carcinoma of the lung. While three fraction SABR is effective for the treatment of early stage non small cell lung carcinoma (NSCLC) of all histologies, it is not safe for many patients. While four and five fraction SABR is safe, recently published data and our institutional data suggests that local control for early stage squamous cell carcinoma of the lung using the current four or five fraction SABR is suboptimal.

Detailed Description: 1. Primary Objectives During Phase I study - Determine the safety and maximum tolerated radiation dose for five fraction SABR for squamous cell cancer of the lung. During Phase II study - Determine 2 year local control of dose escalated five fraction SABR vs. institutional historical control standard dose SABR in squamous cell cancer of the lung. 2. Phase II Secondary Objectives * Determine overall survival, progression free survival and patterns of failure after SABR. * Determine tolerability of dose escalated SABR.